The total duration of this study for each participant is approximately 165 weeks, which includes a screening period of 5 weeks, followed by a 16-week placebo-controlled period which will run concurrently with a 24-week active comparator-controlled period, followed by treatment with JNJ-77242113 200 mg once daily through Week 156 and a 4-week safety follow-up period.
Psoriasis
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
Psoriasis
All genders
18+
Recruiting now
Overview
Principal Investigator: Gabriela Cobos, MD
Contact Us
Alysha Zipeto
Study details
Inclusion Criteria
- Diagnosis of plaque psoriasis, with or without PsA, for at least 26 weeks prior to the
first administration of study intervention - Total BSA ≥10% at screening and baseline
- Total PASI ≥12 at screening and baseline.
Total IGA ≥3 at screening and baseline.
Exclusion Criteria
- Nonplaque form of psoriasis (eg, erythrodermic, guttate, or pustular).
- Previously received deucravacitinib.
- Experienced primary efficacy failure (no response within 16 weeks) or a clinically
significant AE related to agents directly targeting IL-23 or TYK2.
Note: This criterion does not apply to previous IL-12/23 use.
Study Requirements
The study duration will be approximately 160 weeks with 24 study visits.